Recruiting
Phase 1

Apremilast vs. Apremilast

Sponsor:

Amgen

Code:

NCT07908641

Conditions

Psoriasis

Arthritis, Psoriatic

Oral Ulcer

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Interventions

Apremilast XR

Apremilast IR

Study Details

Brief summary:

The main objective of this study is to compare the relative bioavailability, safety, and tolerability of extended-release and immediate-release apremilast formulations in healthy participants.

Conditions

Psoriasis

Arthritis, Psoriatic

Oral Ulcer

Study ID

NCT07908641

Start date

Nov 18, 2026

Status verified date

Nov, 2026

Completion date

Jan 10, 2027

Anticipated

Primary completion date

Jan 10, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Healthy male or female participants, 18 to 60 years of age, inclusive.
  • Body mass index (BMI) between 18.0 and 32.0 kg/m\^²(kilograms per meter square.), inclusive.
  • In good health as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations.
  • Female participants must not be pregnant or breastfeeding.
  • Participants of reproductive potential must agree to follow protocol-specified contraception requirements.

Exclusion Criteria:

  • Clinically significant medical condition or disease that may pose a safety risk or interfere with study participation or interpretation of study results.
  • Clinically significant cardiovascular disease or ECG abnormality, including clinically significant arrhythmia or prolonged QTcF(QT Interval Corrected for Heart Rate Using Fridericia's Formula).
  • Significant gastrointestinal disease, gastrointestinal surgery that could affect drug absorption, malabsorption syndrome, or inability to swallow oral medication.
  • History of suicidal ideation, suicide attempt, or major psychiatric illness within 6 months before informed consent.
  • Malignancy within the previous 5 years, except for protocol-specified nonmelanoma skin cancers or cervical carcinoma in situ.
  • Known hypersensitivity, intolerance, or allergy to apremilast.
  • Clinically significant renal or hepatic impairment, including estimated glomerular filtration rate (eGFR) <70 mL/min/1.73 m\^²(millilitres per minute per 1.73 square meters) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 × the upper limit of normal.
  • Positive testing for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, except for protocol-specified hepatitis B results consistent with prior vaccination or prior infection.
  • Use of prohibited prescription or over-the-counter medications, herbal medicines, vitamins, or supplements within the protocol-specified period before study entry.
  • Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, before check-in.
  • Previous participation in this study or another study investigating apremilast, or previous receipt of apremilast.
  • History of alcohol or drug abuse within the protocol-specified periods, or positive alcohol or illicit drug testing.
  • Use of tobacco- or nicotine-containing products within 3 months before check-in.
  • Recent blood, plasma, or platelet donation outside the protocol-specified limits.
  • Poor peripheral venous access.
  • Unable or unwilling to comply with protocol-required dietary, lifestyle, or other study restrictions.

Study Design

Enrollment

114 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Treatment Sequence AB

Participants will be administered apremilast in the following sequence:

Period 1 (treatment A) - apremilast extended-release (XR) oral tablets given once daily (QD).

Period 2 (treatment B) - apremilast immediate-release (IR) oral tablets given twice daily(BID).

active comparator: Treatment Sequence BA

Participants will be administered apremilast in the following sequence:

Period 1 (treatment B) - apremilast IR oral tablets given BID. Period 2 (treatment A) -. apremilast XR oral tablets given QD.

Interventions

Apremilast XR

Participants will receive apremilast XR orally.

Apremilast IR

Participants will receive apremilast IR orally .

Primary outcome measure

  • Area Under the Plasma Concentration-time Curve (AUC) from Time Zero extrapolated to Infinity (AUCinf) of Apremilast. [ Time Frame: Pre-dose on Day 1 through Day 4 of each treatment period ]
  • Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Apremilast [ Time Frame: Pre-dose on Day 1 through Day 4 of each treatment period ]
  • Maximum Observed Plasma Concentration (Cmax) of Apremilast. [ Time Frame: Pre-dose on Day 1 through Day 4 of each treatment period ]

Central Contacts and Locations

Central contacts

Locations

Fortrea Clinical Research Unit - Daytona Beach

Recruiting

Daytona Beach, Florida, United States, 32117-5116

Fortrea Clinical Research Unit - Dallas

Recruiting

Dallas, Texas, United States, 75247-4968

More Information

Sponsor

Amgen

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Keywords

  • Apremilast
  • Pharmacokinetics
  • Bioavailability
  • Extended-release
  • Immediate-release
  • Crossover Study

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Amgen on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.